| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6093035 | Gastroenterology | 2014 | 48 Pages |
Abstract
Patients with stage III, CIMP-positive, MMR-intact colon tumors have longer survival times when irinotecan is added to combination therapy with fluorouracil and leucovorin.
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Stacey Shiovitz, Monica M. Bertagnolli, Lindsay A. Renfro, Eunmi Nam, Nathan R. Foster, Slavomir Dzieciatkowski, Yanxin Luo, Victoria Valinluck Lao, Raymond J. Jr., Mary J. Emond, Nancy Maizels, Donna Niedzwiecki, Richard M. Goldberg, Leonard B. Saltz,